Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

In a 4-week Phase 1 combination study that was conducted in 50 treatment- naive patients chronically infected with HCV genotype 1, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Eighty-five percent (85%) of patients receiving R7128 1500mg twice- daily (BID) with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under th
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... decades as a manufacturing state, Ohio is positioning itself to ... jobs market. A recent Forbes article ranked Columbus, ... optimistic outlooks for other major Ohio cities. The magazine credits ... home to major research universities. Another contributing ...
... and TORONTO, Dec. 19, 2011 Generex Biotechnology ... scheduled to air a segment on the immunotherapeutic ... subsidiary, Antigen Express, Inc.  The segment is scheduled ... PST) today, Monday, December 19, 2011 (see promo ...
... Inc. announced today that it has entered into ... Biotech, Inc.  The agreement is based on Metamark,s ... specific proprietary cancer targets demonstrated to play a ... (Prognosis Determinants™). The collaboration will focus on the ...
Cached Biology Technology:Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 2Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 3Ohio's Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State 4Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 2Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 3Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today 4Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech 2
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
(Date:4/23/2014)... the source of a unique rhythmic sound, recorded for ... is the Antarctic minke whale ( Balaenoptera bonaerensis ). ... 1960s who thought it sounded like a duck, the ... the Southern Ocean, but its source has remained a ... team of researchers deployed acoustic tags on two Antarctic ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Picky male black widow spiders prefer well-fed virgins 2Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... has a photo of a cornfield and a big photovoltaic ... Washington University in St. Louis. "When I give talks I ... the audience votes overwhelmingly in favor of photosynthesis. " ... (below) is the point of departure for a provocative article ...
... trials prove successful, a new discovery published in ... a major scientific leap toward human tissue regeneration and ... provide evidence to support a major paradigm shift in ... to a graft before implantation are the building blocks ...
... Cancer studies from Mercer University (Ga.) headline groundbreaking ... of Pharmaceutical Scientists, (AAPS) National Biotechnology Conference (NBC). The ... at the Hilton San Francisco Union Square. ... Cervical cancer is the second most common ...
Cached Biology News:Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6Yale scientists discover new method for engineering human tissue regeneration 2AAPS national biotechnology conference to highlight breakthrough cancer treatments 2
... The Yeast ProtoArray high-density functional protein microarray ... rapid elucidation of proteinprotein interactions on a ... S. cerevisiae open reading frames (ORFs) expressed ... duplicate on a 1 inch x 3 ...
... Useful for the mechanical harvesting of cells ... ensures even contact with the growth surface ... 75cm flasks • Individually wrapped • Sterilized ... This CLS number is a new product ...
... use with dishes and cell culture clusters. ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ... Comp Dim: blade L 1.9 cm handle ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Biology Products: